Samsung Bioepis Announces FDA Approval of 420 mg Multi-dose Vial of ONTRUZANT® (trastuzumab-dttb)
●150 mg and 420 mg vial of ONTRUZANT® are now approved INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis…
●150 mg and 420 mg vial of ONTRUZANT® are now approved INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis…
NANJING, China--(BUSINESS WIRE)--IASO Biotherapeutics (IASO BIO) today announced the completion of $60 million in series…
Revenues Reached Record High Of US$820.8M Adjusted Ebitda Breakeven in Second Half of 2019 (Excluding…
DUBLIN--(BUSINESS WIRE)-- The "Europe & Asia Pacific Kraft Papers Market Outlook and Projections, 2019-2027" report…
GUANG’AN, China--(BUSINESS WIRE)--Guang’an, a peaceful and beautiful city in the east of China’s Sichuan Province,…
GUANG’AN, China--(BUSINESS WIRE)--Guang’an, a peaceful and beautiful city in the east of China’s Sichuan Province,…
TOKYO--(BUSINESS WIRE)--Does competitiveness of agribusiness really increase in ASEAN? The answer is yes according to…
OSLO, Norway--(BUSINESS WIRE)--In the race to roll out modern, feature-rich smartphones, China's giant Xiaomi has…
Telehealth System Combines Radius PPG™ Tetherless Pulse Oximetry and the Doctella™ Platform IRVINE, Calif. &…
SHANGHAI--(BUSINESS WIRE)--EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the…